Wockhardt LimitedNSE: WOCKPHARMA

Press Release May 28 2026

· Issued by Wockhardt Limited via NSE India

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Wockhardt Limited has announced that the Indian drug regulator has granted marketing authorization for its antibiotic ZAYNICH® for treating complicated urinary tract infections. The press release highlights ZAYNICH®'s potential as a life-saving option against resistant infections, particularly in cases where current treatments are limited.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release titled, Indian drug regulator grants marketing authorization to Wockhardt's breakthrough antibiotic, ZAYNICH® (Zidebactam/ Cefepime), for treatment of complicated urinary tract infections including pyelonephritis with concurrent Gram-negative bacteremia.

Wockhardt Limited on 6ix

Earlier from Wockhardt

Later from Wockhardt

All Wockhardt news releases